Screener
Generate Biomedicines, Inc. GENB Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | $6,314 | $10,130 | $13,538 | $18,948 |
| Operating expenses: | ||||
| Research and development(1) | 64,330 | 59,735 | 122,142 | 106,560 |
| General and administrative(2) | 13,598 | 10,545 | 27,122 | 20,692 |
| Total operating expenses | 77,928 | 70,280 | 149,264 | 127,252 |
| Loss from operations | (71,614) | (60,150) | (135,726) | (108,304) |
| Other income (expense), net | ||||
| Change in fair value of convertible preferred stock warrant liability | — | — | (363) | — |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s total revenue?
- Generate Biomedicines, Inc. (GENB) reported total revenue of $6.31M in Q2 2026.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Generate Biomedicines, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude